Friday, May 30, 2025

Latest

Mind Medicine Sees CEO Sell $24.7 Million In Company Stock

It appears that uplisting to the Nasdaq is good for business. Or, at least for liquidity, as per insider action that was reported on Mind Medicine (NEO: MMED) (NASDAQ: MNMD) last night. The company has seen its CEO, JR Rahn, sell off a significant portion of his holdings in the company.

As per filings made last night, the firms chief executive has sold off approximately $24.7 million in company stock over the course of approximately one week. Sales consisted of subordinate voting shares of the issuer, as well as the exercise of options and restricted share units.

In total, Rahn sold 6.45 million subordinate voting shares of the issuer, after having exercised a total of 1.9 million options and 727,187 restricted share units. Following the transaction, Rahn now holds 5.3 million options, 2.0 million RSU’s, and just 1.7 million subordinate voting shares.

It’s believed that on a cumulative basis, the sale represented approximately 38% of Rahn’s total position in the company once factoring in subordinates shares, options, and RSU’s.

—–
Correction: As a result of multiple voting shares, it appears that only 38% of Rahn’s position was sold, rather than the originally stated 44%.
—-

Mind Medicine last traded at $3.79 on the NEO.


Information for this briefing was found via Sedar, Sedi and MindMed. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Leave a Reply

Video Articles

How To Profit From $3300 Gold? An Inside Look At A Massive 300,000 Oz Project | Martino De Ciccio

We’re At The Start of a Great Silver Boom | Ross McElroy & Andy Bowering – Apollo Silver Corp

Equinox Gold Q1 Earnings: When Everything Goes Wrong

Recommended

Sterling Metals Hits 0.21% Copper Over 482.8 Metres In First Drilling At Soo Copper project

First Majestic Makes Second Major Discovery At Santa Elena In Just A Year

Related News

MindMed Presents Positive Data Studying LSD In Treating Anxiety Disorders

Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, announced today that its top...

Wednesday, May 11, 2022, 10:27:55 AM

MindMed Declares US$17.0 Million Net Loss, US$105.7 Million Cash Balance For Q2 2022

Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, announced on Thursday its financial...

Friday, August 12, 2022, 08:20:03 AM

Shroom Progress! MindMed Advances Towards a Phase 2 LSD Microdosing Trial For Adult ADHD

Aftermarket MindMed (NEO:MMED) announced they entered into a clinical trial agreement with Maastricht University to...

Monday, May 11, 2020, 10:29:04 PM

Psychedelics & The Need For Digital Therapeutic Solutions In Treating Mental Health

In terms of investment dollar inflows, one of the largest focuses of 2020 has arguably...

Sunday, November 1, 2020, 09:00:00 AM

MindMed Starts Clinical Trial For Intravenous DMT

Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, announced today the start of...

Wednesday, July 28, 2021, 10:22:00 AM